US Pharma MarketingAn interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
Source: BioPharma Dive